Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Argent Capital Management LLC

Argent Capital Management LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,502 shares of the biopharmaceutical company’s stock after purchasing an additional 1,156 shares during the quarter. Argent Capital Management LLC’s holdings in Halozyme Therapeutics were worth $544,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in HALO. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $27,000. GAMMA Investing LLC increased its position in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Halozyme Therapeutics in the first quarter valued at approximately $52,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on HALO. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, October 4th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. The Goldman Sachs Group upped their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Finally, Morgan Stanley increased their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.44.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $35,583,199.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 1.9 %

Halozyme Therapeutics stock traded down $0.98 during mid-day trading on Thursday, hitting $49.82. 342,411 shares of the company’s stock were exchanged, compared to its average volume of 1,278,068. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $65.53. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The firm has a market capitalization of $6.34 billion, a P/E ratio of 20.99, a PEG ratio of 0.49 and a beta of 1.27. The company’s 50 day simple moving average is $58.39 and its 200-day simple moving average is $51.45.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.68 earnings per share. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.